Navigation Links
CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development
Date:11/16/2007

KIRKLAND, Wash., Nov. 16 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has appointed Tony Colasin as its Director of Business Development and will head CellCyte's aggressive acquisition and technology licensing efforts.

Tony Colasin was former Sr. Director of Business Development for ICOS Corporation. From January 2001 to January 2007, he directed that company's business development during several major product introductions. Mr. Colasin managed M&A investment banking engagements, establishing a screening/evaluation process. He led the development and implementation of ICOS' product licensing review process and standardized valuation techniques (NPV and option valuation), which increased the number of opportunities assessed annually and improved overall capacity for revenue.

Notably, Tony Colasin was responsible for building a urology franchise to leverage the Cialis(R) brand, a treatment for erectile dysfunction successfully launched against Viagra(R). Mr. Colasin led a team that created an integrated business development strategy for the company's urology franchise and was a member of the Cialis(R) pre-commercialization team created to develop ICOS sales force's strategy/configuration and pre-launch activities to establish brand character.

While at ICOS Corporation, he also secured a co-promotion agreement of Androgel: successfully led the cross-functional effort to identify products complementary to Cialis(R) and negotiated and executed a multi-million dollar co-promotion agreement for the ICOS sales force. He is also attributed with negotiating rights to a drug used to treat chronic painful bladder syndrome valued at over $25 million, and establishing a $68 million+ strategic alliance and cross-license agreement with a large, potentially competitive biotechnology company.

Prior to ICOS Corporation, Mr. Colasin was Sr. Finance Manager, Corporate Finance, for Amgen, Inc. from Novem
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Genetics Hold Promise, Challenges for Cancer Care
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
4. Obesity genetics
5. The genetics of MLL leukemogenesis
6. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
9. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
10. Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
11. Response Genetics Reports Third Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , DEL MAR, Calif., Nov. 30 /PRNewswire...ration (Pink Sheets: ADHC) is pleased to announce ...dependent director to the Company,s Board of Direc...s over a 40 year period starting at the Chemical B...artner of Harris, Bretall & McEldowney, San Fr...
(Date:11/30/2009)..., , PHILADELPH...l/ -- , - Exclusive Updates From Elsevier...re Reform and ARRA Momentum , Elsevier, a...on as well,as web-based and electronic health reco...ew online resource center for American Recovery an...
(Date:11/30/2009)... The U.S. Centers for Disease Control and Preventi...he United States are infected with HIV/AIDS. New r... that many of those infected are minorities and do...d for a national strategy to facilitate education ...populations. , The research, which analyzed 90,0...
(Date:11/30/2009)... The University of Navarra Hospital has launched a...efficacy of an immunotherapy treatment. This appro...nes produced from healthy and tumour cells from th...ioblastomas, one of the most aggressive and freque...red to participating patients combined with the st...
(Date:11/30/2009)...lder alcoholics tend to drink heavily more often t...NDAY, Nov. 30 (HealthDay News) -- Older people who...eir younger counterparts, a new report finds, poss... same effect. , According to a study released ...der than 60 consume more than 40 drinks a week, on...
Breaking Medicine News(10 mins):Health News:American Diversified Holdings Corporation Announces Appointment of Independent Director to the Board of the Company 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:Research highlights need for national HIV strategy 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Binge Drinking Not Just a Rite of the Young 2
...P(R),s charitable Sight for Students(R) program an...ception in 1997. The program has funded almost $10...me, uninsured and underinsured children. , , (P...ce, the nation,s largest partnership network worki...
... Treatments , , OTTAWA, March 9 /PRNewswire-First... isotopes and radiopharmaceuticals, today announce...for TheraSphere(R), Yttrium-90 Microsphere (Y-90),...er, faster, and more efficient administration of T...
...d expect to need reading glasses or bifocals durin...ed presbyopia. LASIK, a proven technique for freed...r presbyopia. , , But today, according to result...mpletely eliminated the need for all glasses for 9...
...mex: HH ) today announced that it will release f...before market on Friday, March 13, 2009. The Comp...3, 2009 at 11:00am Eastern Time. , , Conferen...n the Company,s web site located at www.hooperhol...
...f Cosmetic Scientists Meeting , , PROVO, Utah, Ma...nternal free radical generator, age-related NOX (a...ses, Inc. (NYSE: NUS ) links the enzyme to age-r... of Cosmetic Scientists (ASCS), March 2-4, in Yoko...
...Take a Second Look at Patent in a Reexamination Pr... Community , , NEW YORK, March 9 Article One Par...he validity of Merck & Co.,s SINGULAIR U.S. dr...an independent expert join Article One,s opinion t...
Other Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians 2Health News:MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians 3Health News:Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information 2Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 2Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 3Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 4
(Date:11/30/2009)...Newswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MED...ical documentation services, today announced that ...ons, Inc. (Nuance) under which MedQuist will now l...ine and processing software for use in SpeechQ of ...recognition application for all medical discipline...
(Date:11/30/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Diabetes Diagnostics - A Global Market ...164347/Diabetes-Diagnostics---A-Global-Market-Pers...driven by a steady increase in the number of peopl...nd developing parts of the world, and increase in ...
(Date:11/30/2009)...-- Dr. Jocelyn Rapelyea, Associate Director of Bre...University Medical Center in Washington, D.C., dem...t-Specific Gamma Imaging (BSGI) can be localized u...as well, as for pre-operative localization today a...f North America (RSNA). ,, BSGI was conducted u...
Breaking Medicine Technology:MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 3Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 4Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 5Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 6Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 7Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 8Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 9Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Breast Cancer Numbers Dip Most in Wealthy Urban Areas 50200 1Breast Cancer Numbers Dip Most in Wealthy Urban Areas 50200 2The Psychology of Celebrity Worship 50198 1The Psychology of Celebrity Worship 50198 2The Psychology of Celebrity Worship 50198 3Discus Dental Files Suit to Protect BriteSmile 28R 29 Trademark 50197 1Discus Dental Files Suit to Protect BriteSmile 28R 29 Trademark 50197 2
...June 4 AstraZeneca (NYSE:,AZN) today announced th...n,(sNDA) to the U.S. Food and Drug Administration ...RT(R) (budesonide/formoterol fumarate dihydrate),I...eatment of asthma in,pediatric patients ages 6 to ...the long-term maintenance treatment of asthma in p...
... 4 Semafore Pharmaceuticals Inc.,today reported i...ct,candidate, SF1126, a targeted pan-PI3 kinase (P...mors. SF1126 is the first PI3 kinase inhibitor to ...ltiple myeloma trials., The data from the solid t...ed in a twice-weekly I.V. infusion at exposure lev...
Other Medicine Technology:AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors 2Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors 3
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: